In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim ... foundation model technologies – machine learning models that can be ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company to seek approval for the asset in a second condition. Topline data ...
ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback